Interim Management Statement
May 10 2010 - 7:02AM
UK Regulatory
TIDMTLI
RNS Number : 6230L
Alternative Asset Opps PCC Ltd
10 May 2010
10 May 2010
Alternative Asset Opportunities PCC Limited
(the "Company")
Interim Management Statement
This interim management statement relates to the period from 1 March 2010 to the
date of publication of this statement and has been prepared solely to provide
additional information in order to meet the relevant requirement of the UK
Listing Authority's Disclosure and Transparency Rules, and should not be relied
on by Shareholders, or any other party, for any other purpose.
The Company is a closed-ended Guernsey protected cell company with one cell
known as the US Traded Life Interests Fund (the "Fund").
Investment objective
The Company's investment objective in respect of the Fund is to provide
investors with an attractive capital return through investment predominantly in
a diversified portfolio of U.S. Traded Life Interests ("TLIs").
Financial position and performance
Over the period to 31 March 2010, the Company's net asset value per share
increased by 3.0% to 86.0 pence. As at 31 March 2010, the shares were trading at
a 21.5% discount to net asset value.
One mortality was accounted for in the period with a total face value of US$3.1
million. There have been, in aggregate, 24 policy maturities since the Fund's
inception.
The Company's loan agreement with Allied Irish Banks plc was renewed in February
2010, and this provides the Company with the ability to borrow up to
US$33,156,000 until 31 January 2011. As of 31 March 2010 total borrowings under
the agreement amounted to US$25,156,000. Since that date a further US$2 million
has been drawn down under the agreement and US$3,109,000 has been repaid to AIB,
leaving a current balance of US$24,047,000.
The Board is not aware of any other material events during the period from 1
March 2010 to 31 March 2010, or in the period from 1 April 2010 to the date of
this announcement, which would have had a material impact on the financial
position of the Company.
Illustrative predicted yields
The table below sets out the range of illustrative predicted yields over the
remaining life of the Company, with reference to the 31 March 2010 NAV of 86.0
pence per share.
+----------+----------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| | | 31 December 2012 | 31 December 2016 |
+---------------------------+---------+-------------------------------------------+--------------------------------------------+
| | | | | IRR based on | | | IRR based on |
| | | | | exit price | | | exit price |
| | | | | range5: | | | range5: |
+---------------------------+---------+------------+-----------+------------------+------------+-----------+-------------------+
| Variation in | LE | Policies |Remaining | 100%6 | 70%7 | Policies |Remaining | 100%6 | 70%7 |
| mortality1 | change |surviving3 |Shares in | | |surviving3 |Shares in | | |
| |(years) | | force 4 | | | | force 4 | | |
| | 2 | | | | | | | | |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| 125% | -1.09 | 58.9% | 71.6% |16.55% | 2.77% | 23.0% | 17.8% | 15.18% | 9.32% |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| 110% | -0.48 | 62.5% | 86.2% |13.29% | -0.11% | 26.8% | 25.2% | 11.58% | 5.91% |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| 100% | 0.00 | 65.1% | 96.0% |11.07% | -2.07% | 29.8% | 33.1% | 9.29% | 3.73% |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| 80% | +1.20 | 70.6% | 100.0% | 6.54% | -6.06% | 37.0% | 55.1% | 4.76% | -0.57% |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| 50% | +4.12 | 80.1% | 100.0% |-1.71% |-13.33% | 52.0% | 100.0% | -3.72% | -8.61% |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| 30% | +8.00 | 87.4% | 100.0% |-8.78% |-19.57% | 66.3% | 100.0% |-17.76% |-21.94% |
+---------------------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| | Ignore | n/a | 79.4% | 100.0% | 0.30% |-11.56% | 43.2% | 82.4% | 2.21% | -2.99% |
| | Medical | | | | | | | | | |
| |Underwriting8 | | | | | | | | | |
+----------+----------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
| | | | | | | | | | | |
+----------+----------------+---------+------------+-----------+--------+---------+------------+-----------+---------+---------+
Notes
1. The central case (100%) assumes that claims experience matches the
valuation basis in force at 31 March 2010. The other scenarios assume that the
mortality experience is higher (e.g. 110% means that if one expects 10 deaths,
one instead experiences 11) or lower (e.g. 80% means that if one expects 10
deaths, one instead experiences 8).
2. This shows the effect of the mortality experience on the life expectancy
(in years) for an otherwise normal 80-year-old non-smoker.
3. The proportion of policies surviving to the specified date based on the
portfolio as at 31 March 2010. No allowance has been made for the policies that
have matured after this date.
4. The model assumes that shares are repurchased whenever excess cash
beyond that required for premium reserves is available. This column represents
the number of shares still in force and not repurchased at the relevant date.
5. This shows how the return varies for a shareholder holding the shares
between 31 March 2010 and the relevant date (31 December 2012 or 31 December
2016) based on the growth in the NAV per share.
6. Return based on growth in NAV per share assuming valuation at the
relevant date using the valuation basis in force at 31 March 2010.
7. Return based on winding up at the relevant date assuming that the net
realised proceeds of assets is 70% of the valuation calculated in accordance
with the valuation basis in force at 31 March 2010.
8. Mortality outcome assuming the lives are all "normal" lives from the
point of view of mortality expectations and ignoring the implied relative health
from medical underwriting.
Source: SL Investment Management Limited
Top ten holdings
By reference to the most recent portfolio valuation of the Company as at 31
March 2010, the largest ten investments held by the Company, measured by life
office exposure, were as follows:
+----------------------------------------------+----------+-------------+
| Issuer | Number | % of total |
| | of | assets as |
| | policies | at |
| | | 31 March |
| | | 2010 |
+----------------------------------------------+----------+-------------+
| American General Life Insurance Company (TX) | 13 | 16.18% |
+----------------------------------------------+----------+-------------+
| Lincoln National Life Insurance Co | 18 | 13.65% |
+----------------------------------------------+----------+-------------+
| Transamerica Life Insurance Company | 21 | 13.44% |
+----------------------------------------------+----------+-------------+
| John Hancock Life Insurance Company | 13 | 9.24% |
+----------------------------------------------+----------+-------------+
| Massachusetts Mutual Life Insurance Co | 10 | 9.11% |
+----------------------------------------------+----------+-------------+
| Aviva Life and Annuity Company | 6 | 6.37% |
+----------------------------------------------+----------+-------------+
| Pacific Life Insurance Company | 6 | 5.99% |
+----------------------------------------------+----------+-------------+
| MetLife Insurance Company of Connecticut | 8 | 4.32% |
+----------------------------------------------+----------+-------------+
| New York Life Insurance and Annuity Corp | 6 | 3.54% |
+----------------------------------------------+----------+-------------+
| Security Life of Denver Insurance Co | 1 | 3.24% |
+----------------------------------------------+----------+-------------+
Company Information
Launch date 25 March 2004
EPIC TLI
Year end 30 June (from 2010 onwards)
Report & Accounts 2009 Annual Report posted December, Interim posted May
AGM November
Price Information Financial Times (under INVESTMENT COMPANIES, listed
as 'AltAstsOpps.')
Investor Information
The latest available portfolio information included in the interim and annual
report and accounts can be accessed via
http://www.rcm.com/investmenttrusts/investors_tlif.php (under the Professional
Investors section)
By order of the Board
Alternative Asset Opportunities PCC Limited
Enquiries:
Peter Ingram
Company Secretary
Tel: 020 7065 1467
This information is provided by RNS
The company news service from the London Stock Exchange
END
IMSGGUPUAUPUGGU
Alternative Asset Opps Pcc (LSE:TLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alternative Asset Opps Pcc (LSE:TLI)
Historical Stock Chart
From Jul 2023 to Jul 2024
